Valanbio Therapeutics, Inc.
Durham, NC
- UEI
- KKFTU8J72323
- CAGE
- 7GYE0
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 201 Finsbury St, 201 Finsbury St, Durham, NC 27703, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| IND-enabling studies of the potent lpxc inhibitor LPC-233 as a novel antibiotic against gram-negative pathogens | National Institute of Allergy and Infectious Diseases (NIH) | $3,180,429 |
Quick answers
Is Valanbio Therapeutics, Inc. registered in SAM.gov?
Yes. Valanbio Therapeutics, Inc.'s SAM.gov registration is active through December 9, 2026.
What is Valanbio Therapeutics, Inc.'s most recent federal award?
Valanbio Therapeutics, Inc.'s most recent federal grant award is IND-enabling studies of the potent lpxc inhibitor LPC-233 as a novel antibiotic against gram-negative pathogens (R44AI152896), from National Institute of Allergy and Infectious Diseases (NIH), on April 16, 2020.
On GovTribe
See Valanbio Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors